$1.29
Value $95M
HCAT and MU stock compared: price, dividend, valuation and results, from SEC filings.
$1.29
Value $95M
$705.27
Value $798B
Health Catalyst (HCAT) has a market value of $95M and Micron Technology (MU) $798B. Over the last year, with dividends, HCAT moved -42.4% and MU +191.8%. Dividend yield: HCAT none, MU 0.08%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
HCAT$95M
MU$798B
MU is 8,406 times HCAT
Revenue, 12 months
HCAT$272M
MU$133B
MU is 489 times HCAT
Net income, 12 months
HCAT-$202M
MU$85.0B
Operating margin
HCAT-65.7%
MU74.6%
140.3 points apart
ROIC
HCAT-44.9%
MU89.7%
134.5 points apart
P/E
HCAT–
MU9.4
Dividend yield
HCAT0.0%
MU0.1%
0.1 points apart
5-year return
HCAT-97.4%
MU+857.4%
954.8 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
HCAT-97.4%
MU+857.4%
| Period | HCATWith dividends | MUWith dividends |
|---|---|---|
| 1 year since November 17, 2025 | -42.4%Price -42.4% | +191.8%Price +191.5% |
| 3 years since November 17, 2023 | -83.4%-45.1% a yearPrice -83.4% | +818.2%+109.4% a yearPrice +809.3% |
| 5 years since November 17, 2021 | -97.4%-51.8% a yearPrice -97.4% | +857.4%+57.1% a yearPrice +834.6% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
HCATHealth CatalystMUMicron Technology
| Price | $1.29 | $705.27 |
|---|---|---|
| Market value | $95M | $798B |
| Enterprise value (EV) | $16M | $760B |
| P/E | – | 9.4 |
| P/E, 5-year median | – | 12.9 |
| P/B | 0.7 | 5.8 |
| EV/EBIT | – | 7.7 |
| Free cash flow yield | 27.1% | 7.4% |
| Revenue, 12 months | $272M | $133B |
|---|---|---|
| Net income, 12 months | -$202M | $85.0B |
| Free cash flow, 12 months | $26M | $59.0B |
| Earnings per share, 12 months | -$2.85 | $74.33 |
| Revenue growth, year on year | 1.5% | 256.3% |
| Revenue growth a year, past | +10.5%over 5 years | +36.9%over 5 years |
| EPS growth a year, past | – | +70.6%over 5 years |
| Gross margin | 49.1% | 80.7% |
|---|---|---|
| Operating margin | -65.7% | 74.6% |
| Net margin | -74.2% | 63.8% |
| ROIC | -44.9% | 89.7% |
| ROE | -105.0% | 100.1% |
| Cash | $79M | $43.4B |
|---|---|---|
| Total debt | $16M | $5.2B |
| Net debt / EBITDA | – | -0.4 |
| Interest cover | – | 937.2× |
| Dividend yield | – | 0.1% |
|---|---|---|
| Dividend per share, 12 months | – | $0.57 |
| Dividend growth a year, past | – | – |
| Buyback yield | 5.3% | 0.1% |
| Shareholder yield | 5.3% | 0.2% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Micron Technology ($798B) is about 8,406.1 times Health Catalyst ($95M), at today's prices.
Since November 17, 2021, HCAT's price moved -97.4% and MU's +834.6%. With dividends: HCAT -97.4% (-51.8% a year), MU +857.4% (+57.1% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Health Catalyst and 0.08% for Micron Technology. Over the last twelve months they paid – and $0.57 per share.
Over the last twelve months, the net margin was -74.2% for Health Catalyst and 63.8% for Micron Technology, and the operating margin -65.7% and 74.6%. Revenue was $272M and $133B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.